Pharmacokinetic drug interaction between carvedilol and ticlopidine in rats

Biomolecules and Therapeutics

Volumn 18, Issue 3, 2010, Pages 343-349

  Choi, Jun Shik ^a   Choi, Dong Hyun ^a  

^a Chosun University   (South Korea)

Author keywords

Bioavailability; Carvedilol; CYP2C9; P glycoprotein; Pharmacokinetics; Ticlopidine

Indexed keywords

CARVEDILOL; CYTOCHROME P450 2C9; GLYCOPROTEIN P; RHODAMINE 123; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN MCF 7; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

RATTUS;

EID: 77957373560     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2010.18.3.343     Document Type: Article

References (34)

1. Bart, J., Dijkers, E. C., Wegman, T. D., de Vries, E. G., van der Graaf, W. T., Groen, H. J., Vaalburg, W., Willemsen, A. T. and Hendrikse, N. H. (2005). New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol. 145, 1045-1051.
2. Bristow, M. R., Gilbert, E. M., Abraham, W. T., Adams, K. F., Fowler, M. B., Hershberger, R. E., Kubo, S. H., Narahara, K. A., Ingersoll, H., Krueger, S., Young, S. and Shusterman, N. (1996). Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94, 2807-2816.
3. Bristow, M. R., Larrabee, P., Minobe, W., Roden, R., Skerl, L., Klein, J., Handwerger, D. and Port, J. D., Möller-Beckmann B. (1992). Receptor pharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol. 19, S68-80.
4. Buur, T., Larsson, R., Berglund, U., Donat, F. D. V. M. and Tronquet, C. (1997). Pharmocokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J. Clin. Pharmacol. 37, 108-115.
5. Cao, X, Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P, Shin, H. C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X. and Sun, D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675-1686.
6. Cleland, J. G., Bristow, M. R., Erdmann, E., Remme, W. J., Swedberg, K. and Waagstein, F. (1996). Beta-blocking agents in heart failure. Should they be used and how? Eur. Heart J. 17, 1629-1639.
7. Cournot, A., Lim, C., Duchier, J. and Safar, M. (1992). Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J. Cardiovasc. Pharmacol. 19, S35-39.
8. Crespi, C. L., Miller, V. P., Penman, B. W. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190.
9. DasGupta, P., Broadhurst, P. and Lahiri, A. (1991). The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. J. Cardiovasc. Pharmacol. 18, S12-16.
10. Feuerstein, G. Z., Bril, A. and Ruffolo, R. R. Jr. (1997). Protective effects of carvedilol in the myocardium. Am. J. Cardiol. 80, 41L-45L.
11. Gent, M., Blakely, J. A., Easton, J. D., Ellis, D. J., Hachinski, V. C., Harbison, J. W., Panak, E., Roberts, R. S., Sicurella, J. and Turpie, A. G. (1989). The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet. 1, 1215-1220.
12. Gidal, B. E., Sorkness, C. A., McGill, K. A., Larson, R. and Levine, R. R. (1995). Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther. Drug Monit. 17, 33-38.
13. Hampton, J. R. (1996). Beta-blockers in heart failure--the evidence from clinical trials. Eur. Heart J. 17, 17-20.
14. Hass, W. K., Easton, J. D., Adams, H. P. Jr., Pryse-Phillips, W., Molony, B. A., Anderson, S. and Kamm, B. (1989). A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N. Engl. J. Med. 321, 501-507.
15. Haynes, R. B., Sandler, R. S., Larson, E. B., Pater, J. L. and Yatsu, F. M. (1998). A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch. Intern. Med. 152, 1376-1380.
16. Ito, M. K., Smith, A. R. and Lee, M. L. (1992). Ticlopidine: a new platelet aggregation inhibitors. Clin. Pharm. 11, 603-617.
17. Janzon, L., Bergqvist, D., Boberg, J., Boberg, M., Eriksson, I., Lindgärde, F., Persson, G., Almgren, B., Fagher, B. and Kjellström, T., et al. (1990). Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med. 227, 301-308.
18. Kaminsky, L. S. and Fasco M. J. (1991). Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21, 407-422.
19. Ko, J. W., Desta, Z., Soukhova, N. V., Tracy, T. and Flockhart, D. A. (2000). In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C9 and CYP2D6. Br. J. Clin. Pharmacol. 49, 343-351.
20. Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C. and Watkins, P. B. (1992). Identification of rifampin-inducible P450IIIA4 (CYP2C9) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878.
21. Lewis, D. F. V. (1996). Cytochrome P450. Substrate specificity and metabolism. In Cytochromes P450. Structure, Function, and Mechanism, pp. 122-123.
22. Taylor & Francis, Bristol. Lund-Johansen, P., Omvik, P., Nordrehaug, J. E. and White, W. (1992). Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. J. Cardiovasc. Pharmacol. 19, S27-34.
23. McGinnity, D., Tucker, J., Trigg, S. and Riley, R. (2005). Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab. Dispos. 33, 1700-1707.
24. McTavish, D., Campoli-Richards, D. and Sorkin, E. M. (1993). Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45, 232-258.
25. Morgan, T. (1994). Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin. Pharmacokinet. 26, 335-346.
26. Neugebauer, G., Akpan, W., von Mollendorff, E., Neubert, P. and Reiff, K. (1987). Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 11, S85-88.
27. Neugebauer, G. and Neubert, P. (1991). Metabolism of carvedilol in man. Eur. J. Drug Metab. Pharmacokinet. 16, 257-260.
28. Oldham, H. G. and Clarke, S. E. (1997). In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(â̂')-carvedilol. Drug Metab. Dispos. 25, 970-977.
29. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993). P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS. Lett. 324, 99-102.
30. Saltiel, E. and Ward, A. (1987). Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutics efficacy in platelet-dependent disease states. Drugs 34, 222-262.
31. Shah, J., Fratis, A., Ellis, D., Murakami, S. and Teitelbaum, P. (1990). Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J. Clin. Pharmacol. 30, 733-736.
32. Solomon, D. H. and Hart, R. G. (1994). Antithrombotic therapies for stroke prevention. Curr. Opin. Neurol. 7, 48-53.
33. Verhaeghe, R. (1991). Prophylactic antiplatelet therapy in peripheral arterial disease. Drugs 42, 51-57.
34. Zarghi, A., Foroutan, S. M., Shafaati, A. and Khoddam, A. (2007). Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. J. Pharm. Biomed. Anal. 44, 250-253.